Form 4: 180 Life Sciences Corp. Grants Equity Compensation to Chief Accounting Officer

180 Life Sciences Corp. has granted 8,763 restricted common shares and 25,000 non-qualified stock options to Chief Accounting Officer Eric R. Van Lent as part of his compensation.

Summary

• Eric R. Van Lent, Chief Accounting Officer of 180 Life Sciences Corp. (ATNF), was granted equity compensation on June 17, 2025.
• The compensation includes 8,763 shares of common stock, which are restricted and subject to time-based vesting.
• The restricted shares vest in two equal tranches: 1/2 on December 17, 2025, and 1/2 on June 17, 2026, contingent on continued service to the Issuer. These shares were issued under the Issuer's 2022 Equity Compensation Plan.
• Additionally, Mr. Van Lent received 25,000 non-qualified stock options with an exercise price of $0.929 per share and an expiration date of June 17, 2035.
• These options also vest in two equal tranches: 1/2 on December 17, 2025, and 1/2 on June 17, 2026, subject to continued service to the Issuer.
• The stock options were issued under the Issuer's 2025 Option Incentive Plan, which requires stockholder approval; if approval is not obtained, the options will be cancelled.
• Both the restricted shares and options were issued in consideration for services rendered and agreed to be rendered to the Issuer as Chief Accounting Officer.

Sentiment

Score: 6

Explanation: The document reports standard equity compensation, which is generally positive for aligning management incentives but doesn't indicate significant operational news. The contingency of options on shareholder approval introduces a minor element of uncertainty.

Positives

• The issuance of equity compensation aligns management's interests with shareholders' long-term success.
• The compensation package aims to incentivize the Chief Accounting Officer to remain with the company and contribute to its performance.

Negatives

• The 25,000 stock options are contingent on stockholder approval of the 2025 Option Incentive Plan; if not approved, these options will be cancelled.

Risks

• The 25,000 non-qualified stock options granted are subject to stockholder approval of the 2025 Option Incentive Plan; if approval is not obtained, these options will be cancelled.
• Vesting of both restricted stock and options is contingent on the recipient's continued service to the Issuer.

Future Outlook

The future outlook for the granted stock options is contingent on stockholder approval of the 2025 Option Incentive Plan. If approved, the options will vest over time, aligning the Chief Accounting Officer's incentives with the company's long-term performance.

Management Comments

• The equity compensation was issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Accounting Officer of the Issuer.

Industry Context

The granting of equity compensation, including restricted stock and stock options, is a standard practice across various industries, particularly in biotechnology and life sciences, to attract, retain, and incentivize key executives. This practice aligns executive interests with shareholder value creation by tying compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from new share issuance and option exercise, but also potential benefit from incentivized management performance. The 2025 Option Incentive Plan requires shareholder approval, giving them a direct say.
• Employees: The compensation package is specific to the Chief Accounting Officer, but the existence of equity compensation plans (2022 Equity Compensation Plan, 2025 Option Incentive Plan) suggests a broader framework for employee incentives.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan is required for the 25,000 stock options to become exercisable.
• Continued service by Eric R. Van Lent is required for the vesting of both restricted stock and stock options on December 17, 2025, and June 17, 2026.

Key Dates

Keywords

180 Life Sciences Corp., ATNF, SEC Form 4, Equity Compensation, Stock Options, Restricted Stock, Insider Trading, Executive Compensation, Chief Accounting Officer, Employee Retention